Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02981797 · ClinicalTrials.gov registry record
Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223
A clinical trial, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT02981797 is a clinical trial that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 10 participants.
The verdict
NCT02981797 has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This is a prospective biomarker study on prostate cancer patients receiving Radium 223 as standard of care. Participants will take part in this research study because they have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Investigators want to find out if a blood test performed before and after the Radium 223 treatment will help to understand how prostate cancer cells react to this therapy. In this pilot study, researchers want to find out if Radium 223 given as part of standard treatment for prostate cancer can decrease the number of circulating prostate cancer cells. Radium 223 kills prostate cancer cells by damaging their DNA. Other than looking at the changes in the number of circulating prostate cancer cells before and after Radium 223, researchers would also like to look at the changes in a DNA damage marker, called gamma H2AX, in the circulating prostate cancer cells before and after treatment with Radium 223. Assessing the DNA damage marker gamma H2AX is investigational. It is performed in the same tube of blood that is used for assessing the changes in the number of circulating prostate cancer cells.
Interventions
- OTHER Blood Collection During Standard of Care Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-07-22 |
| Est. Completion | 2020-11-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02981797
The ClinicalTrials.gov registry entry for NCT02981797 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Collection During Standard of Care Treatment is the first listed.
NCT02981797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02981797 about?
NCT02981797 is a clinical study titled "Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223". This is a prospective biomarker study on prostate cancer patients receiving Radium 223 as standard of care. Participants will take part in this research study because they have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Investigators want to ...
What is the current status of trial NCT02981797?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2015-07-22. Estimated completion is 2020-11-05.
What interventions are being tested in trial NCT02981797?
The interventions under investigation include: Blood Collection During Standard of Care Treatment (OTHER).
Who is sponsoring clinical trial NCT02981797?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.